Disposition and biotransformation of the acetylenic retinoid tazarotene in humans

Journal of Pharmaceutical Sciences

Volumn 94, Issue 10, 2005, Pages 2246-2255

  Attar, Mayssa ^a   Yu, Dale ^a   Ni, Jinsong ^a   Yu, Zhiling ^a   Ling, Kah Hiing John ^a   Tang Liu, Diane D S ^a  

^a ALLERGAN INC   (United States)

Author keywords

ADME; HPLC; Human; Mass spectrometry; Metabolism; Retinoids

Indexed keywords

ACETYLENE DERIVATIVE; CARBON 14; DRUG METABOLITE; ESTERASE; RETINOID; TAZAROTENE; TAZAROTENIC ACID SULFOXIDE; UNCLASSIFIED DRUG;

ACNE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PLASMA; PSORIASIS; RADIOACTIVITY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

EID: 27944509054     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20427     Document Type: Article

References (18)

1. Shalita AE, Chalker DK, Griffith RF, Herbert AA, Hickman JG, Maloney JM, Miller BH, Tschen EH, Chandraratna RA, Gibson JR, Lew-Kaya DA, Lue JC, Sefton J. 1999. Tazarotene gel is safe and effective in the treatment of acne vulgaris: A multicenter, double-blind, vehicle-controlled study. Cutis 63:349-354.
2. Weinstein GD. Tazarotene gel: Efficacy and safety in plaque psoriasis. 1997. J Am Acad Dermatol 37:833-838.
3. Phillips TJ, Gottlieb AB, Leyden JJ, Löwe NJ, Lew-Kaya DA, Sefton J, Walker PS, Gibson JR. 2002. Efficacy of 0.1% tazarotene cream for the treatment of photodamage: A 12-month multicenter, randomized trial. Arch Dermatol 138:1486-1493.
4. Nagpal S, Athanikar J, Chandraratna RA. 1995. Separation of transactivation and API antagonism functions of retinoic acid receptor alpha. J Biol Chem 270:923-927.
5. Chandraratna RA. 1996. Tazarotene-first of a new generation of receptor-selective retinoids. Br J Dermatol 135:18-25.
6. DiSepio D, Ghosn C, Eckert RL, Deucher A, Robinson N, Duvic M, Chandraratna RA, Nagpal S. 1998. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc Natl Acad Sci USA 95: 14811-14815.
7. Tang-Liu DD, Matsumoto RM, Usansky JI. 1999. Clinical pharmacokinetics and drug metabolism of tazarotene: A novel topical treatment for acne and psoriasis. Clin Pharmacokinet 37:273-287.
8. Yu Z, Sefton J, Lew-Kaya D, Walker P, Yu D, Tang-Liu DD. 2003. Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin. Clin Pharmacokinet 42:921-929.
9. Walker PS, Menter MA, Weinstein GD, Gibson JR, Tang-Liu DDS, Lowe NJ. 2002. Oral tazarotene for the treatment of moderate to severe plaque psoriasis. Br J Dermatol 147:1061-1062.
10. Lee E, Borbridge LM, Walker PS, Suri A, Tang-Liu DD, Yu DK. 2002. Pharmacokinetics and dose proportionality of tazarotene following oral administration in healthy subjects. Pharmacotherapy 22:1364.
11. Madhu C, Duff S, Baumgarten V, Rix P, Small D, Tang-Liu D. 1997. Metabolic deesterification of tazarotene in human blood and rat and human liver microsomes. J Pharm Sci 86:972-974.
12. Attar M, Dong D, Ling KH, Tang-Liu DD. 2003. Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab Dispos 31:476-481.
13. Brecher AE, Orlow SJ. 2003. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol 49:171-182.
14. Webster GF. 2002. Acne vulgaris. Br Med J 325: 475-479.
15. Fleischer AB Jr., Simpson JK, McMichael A, Feldman SR. 2003. Are there racial and sex differences in the use of oral isotretinoin for acne management in the United States? J Am Acad Dermatol 49: 662-666.
16. McCaffery PJ, Adams J, Maden M, Rosa-Molinar E. 2003. Too much of a good thing: Retinoic acid as an endogenous regulator of neural differentiation and exogenous teratogen [review]. Eur J Neurosci 18:457-472.
17. Larsen FG, Nielsen-Kudsk F, Jakobsen P, Weismann K, Kragballe K. 1992. Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases. Clin Pharmacokinet 23:42-61.
18. Liu SS, Sandri R, Tang-Liu DD. 1990. Systemic pharmacokinetics of acetylenic retinoids in rats. Drug Metab Dispos 18:1071-1077.